Elite in Juvenile Myelomonocytic Leukemia (JMML)

Andre Baruchel

Paris, FR 
Elite in Juvenile Myelomonocytic Leukemia (JMML)
Paris, FR 
OverviewLocationsClinical Research

Overview

Andre Baruchel practices in Paris, France. Mr. Baruchel is rated as an Elite expert by MediFind in the treatment of Juvenile Myelomonocytic Leukemia (JMML). His top areas of expertise are Acute Lymphoblastic Leukemia (ALL), Leukemia, Juvenile Myelomonocytic Leukemia (JMML), Childhood Acute Myeloid Leukemia, and Bone Marrow Transplant.

His clinical research consists of co-authoring 285 peer reviewed articles and participating in 1 clinical trial. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 6 articles in the study of Juvenile Myelomonocytic Leukemia (JMML).

Gender
Male

Locations

Paris, France
Other Locations
Robert, France
Saint-etienne-de-valoux, 75012, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

A Pivotal Phase 1/2, Single-Arm, Open-label Study to Evaluate the Safety and Efficacy of Ponatinib With Chemotherapy in Pediatric Patients With Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) Who Have Relapsed or Are Resistant or Intolerant to a Prior Tyrosine Kinase Inhibitor-Containing Therapy, or Who Have the T315I Mutation
A Pivotal Phase 1/2, Single-Arm, Open-label Study to Evaluate the Safety and Efficacy of Ponatinib With Chemotherapy in Pediatric Patients With Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) Who Have Relapsed or Are Resistant or Intolerant to a Prior Tyrosine Kinase Inhibitor-Containing Therapy, or Who Have the T315I Mutation
Enrollment Status: Terminated
Publish Date: October 02, 2025
Intervention Type: Drug
Study Drug: Ponatinib
Study Phase: Phase 1/Phase 2

285 Total Publications

Toward chemotherapy-reduced cure for TCF3::HLF B-cell acute lymphoblastic leukemia using CD-19-directed immunotherapy.
Toward chemotherapy-reduced cure for TCF3::HLF B-cell acute lymphoblastic leukemia using CD-19-directed immunotherapy.
Journal: Haematologica
Published: August 04, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Baruchel's expertise for a condition
ConditionClose
View All 18 Advanced Conditions
View All 55 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile